menu
    • menu

    Company profile for Polyrizon

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Polyrizon Ltd. is a development-stage biotechnology company specializing in innovative intranasal products. Their proprietary Capture & Contain™ (C&C) hydrogel technology, delivered as nasal sprays, forms a thin barrier in the nasal cavity to protect against viruses and allergens. Additionally, their Trap & Target™ (T&T) platform is advancing intranasal drug delivery methods. Recently, Polyrizon initiated the Good Manufact...
    Polyrizon Ltd. is a development-stage biotechnology company specializing in innovative intranasal products. Their proprietary Capture & Contain™ (C&C) hydrogel technology, delivered as nasal sprays, forms a thin barrier in the nasal cavity to protect against viruses and allergens. Additionally, their Trap & Target™ (T&T) platform is advancing intranasal drug delivery methods. Recently, Polyrizon initiated the Good Manufacturing Practice (GMP) manufacturing process for its PL-14 allergy blocker, preparing for a planned clinical trial in 2025.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PolyrizonIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    HaTidhar St. 5 Raanana
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://polyrizon-biotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Polyrizon Closes $3.5M in Direct and Private Placements
    Polyrizon Closes $3.5M in Direct and Private Placements

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3270529/0/en/Polyrizon-Ltd-Announces-Closing-of-3-5-Million-Registered-Direct-and-Private-Placements.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share
    Polyrizon Announces $3.5M Direct Offering and Private Placement
    Polyrizon Announces $3.5M Direct Offering and Private Placement

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3269086/0/en/Polyrizon-Ltd-Announces-3-5-Million-Registered-Direct-Offering-and-Private-Placement.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    Polyrizon Provides 2025 And Recent Highlights
    Polyrizon Provides 2025 And Recent Highlights

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263127/0/en/Polyrizon-Provides-2025-and-Recent-Highlights.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Polyrizon Ltd. Submits 20-F Annual Report For 2025 Fiscal Year
    Polyrizon Ltd. Submits 20-F Annual Report For 2025 Fiscal Year

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262640/0/en/Polyrizon-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31-2025.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    Polyrizon Intends to Acquire up to 20% Stake in Colugo
    Polyrizon Intends to Acquire up to 20% Stake in Colugo

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261255/0/en/Polyrizon-Intends-to-Acquire-up-to-20-Stake-in-Colugo-Developer-of-Advanced-eVTOL-Drones-for-Defense-and-Urban-Air-Mobility-Applications.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    Polyrizon Inks Deal with Global CRO for Trials
    Polyrizon Inks Deal with Global CRO for Trials

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257164/0/en/Polyrizon-Signs-an-Agreement-with-Leading-Global-Preclinical-CRO-as-Part-of-Clinical-Development-Program.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search